Infliximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Infliximab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
544
Registered trials
922
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Infliximab can convert its Monoclonal antibody profile and TNF-α biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Infliximab (query alias: infliximab) |
|---|---|
| Modality / target | Monoclonal antibody; TNF-α; TNF-α inhibitors |
| Highest global status | Approved |
| Originator | Janssen Global Services LLC |
| Active developers | Janssen-Cilag International NV, Janssen Biotech, Inc., Tanabe Pharma Corp. |
The MCP disease footprint includes Mucocutaneous Lymph Node Syndrome, Behcet's uveitis, Erythrodermic psoriasis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07683975 | Phase 4 | Not yet recruiting | 44 | Acute kidney injury recovery at 12 weeks |
| NCT07671222 | Phase 2 | Not yet recruiting | 38 | Change in Ocular Surface Disease Index (OSDI) |
| NCT07657312 | Phase 2 | Recruiting | 35 | Incidence of all-grade cytokine release syndrome (CRS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
COMPARISON OF THE RISK OF ACUTE ANTERIOR UVEITIS FLARE BETWEEN ADALIMUMAB AND SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND PRIOR ACUTE ANTERIOR UVEITIS: A RANDOMIZED CONTROLLED TRIAL
Not Applicable; n=56; evaluation: Positive. Reported fields: AAU flare = 1.0 Pts ; AAU flare = 1.0 Pts
COMPARATIVE LONG-TERM CLINICAL AND VASCULAR IMAGING OUTCOMES OF TOCILIZUMAB VERSUS INFLIXIMAB IN TAKAYASU’S ARTERITIS: A REAL-WORLD IPTW-ADJUSTED ANALYSIS FROM INDIA
Not Applicable; n=74; evaluation: Positive. Reported fields: Clinical disease activity(inactive) = 62.5 % ; Clinical disease activity(inactive) = 14.3 %
REAL-WORLD EFFECTIVENESS AND DRUG SURVIVAL OF INFLIXIMAB IN REFRACTORY MULTISYSTEM SARCOIDOSIS: A MULTICENTRE COHORT STUDY
Not Applicable; n=82; evaluation: Positive. Reported fields: Treatment Success(6-month) = 41.0 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Infliximab addresses Mucocutaneous Lymph Node Syndrome, Behcet's uveitis, Erythrodermic psoriasis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-09-16 | Mitsubishi Tanabe Pharma Corporation will conclude co-promotion activities for the human anti-human IL-12/23p40 monoclonal antibody formulation "Stelara® " | Approved | Financial terms not disclosed |
| 2021-06-17 | Nichi-Iko Licenses Its Remicade Biosimilar to Argentine Drug Maker | Approved | Financial terms not disclosed |
| 2020-06-25 | Diversigen and Alimentiv collaborate on the PROTOS clinical trial, investigating the use of infliximab in patients with ASUC. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Detection method and detection kit for TNF alpha drug-resistant antibody”. The milestone feed surfaced a patent-application signal described as “Preparation method of infliximab freeze-dried preparation for injection”. The milestone feed surfaced a patent-application signal described as “Anti-TNF alpha agent for treating coronavirus infections”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
